Stochastic Pharmacokinetic/Pharmacodynamic Modeling for Assessing the Systemic Health Risk of Perfluorooctanoate (PFOA)

Convertino Convertino, Timothy Church, Geary Olsen, Yang Liu, Eddie Doyle, Clifford Elcombe, Anna Barnett, Leslie Samuel, Iain MacPherson, Thomas Evans

Research output: Contribution to journalArticle

10 Citations (Scopus)
4 Downloads (Pure)

Abstract

A phase 1 dose-escalation trial assessed the chemotherapeutic potential of ammonium perfluorooctanoate (APFO). Forty-nine primarily solid-tumor cancer patients who failed standard therapy received weekly APFO doses (50–1200 mg) for 6 weeks. Clinical chemistries and plasma PFOA (anionic APFO) were measured predose and weekly thereafter. Several clinical measures including total cholesterol, high-density lipoproteins (HDLs), thyroid stimulating hormone (TSH), and free thyroxine (fT4), relative to PFOA concentrations were examined by: Standard statistical analyses using generalized estimating equations (GEE) and a probabilistic analysis using probability distribution functions (pdf) at various PFOA concentrations; and a 2-compartment pharmacokinetic/pharmacodynamic (PK/PD) model to directly estimate mean changes. Based on the GEE, the average rates of change in total cholesterol and fT4 associated with increasing PFOA were approximately ﰀ1.2ﰁ10ﰀ3 mmol/l/lM and
2.8ﰁ10ﰀ3 pmol/l/lM, respectively. The PK/PD model predicted more closely the trends observed in the data as well as the pdfs of biomarkers. A decline in total cholesterol was observed, with a clear transition in shape and range of the pdfs, manifested by the maximum value of the Kullback-Leibler (KL) divergence, that occurred at plasma PFOA between 420 and 565 lM (175 000–
230 000 ng/ml). High-density lipoprotein was unchanged. An increase in fT4 was observed at a higher PFOA transition point, albeit TSH was unchanged. Our findings are consistent with some animal models and may motivate re-examination of the epidemiologic studies to PFOA at levels several orders of magnitude lower than this study. These observational studies have reported contrary associations, but currently understood biology does not support the existence of such conflicting effects.
Original languageEnglish
Pages (from-to)293-306
Number of pages14
JournalToxicological Sciences
Volume163
Issue number1
Early online date16 Feb 2018
DOIs
Publication statusPublished - 1 May 2018

Fingerprint

perfluorooctanoic acid
Pharmacodynamics
Pharmacokinetics
Health risks
Health
Thyrotropin
Cholesterol
Plasmas
Clinical Chemistry

Keywords

  • APFO
  • phase 1 trial
  • PK/PD modeling
  • cholesterol
  • PFOA
  • thyroid

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Stochastic Pharmacokinetic/Pharmacodynamic Modeling for Assessing the Systemic Health Risk of Perfluorooctanoate (PFOA). / Convertino, Convertino; Church, Timothy; Olsen, Geary; Liu, Yang; Doyle, Eddie; Elcombe, Clifford; Barnett, Anna; Samuel, Leslie; MacPherson, Iain; Evans, Thomas.

In: Toxicological Sciences, Vol. 163, No. 1, 01.05.2018, p. 293-306.

Research output: Contribution to journalArticle

Convertino, C, Church, T, Olsen, G, Liu, Y, Doyle, E, Elcombe, C, Barnett, A, Samuel, L, MacPherson, I & Evans, T 2018, 'Stochastic Pharmacokinetic/Pharmacodynamic Modeling for Assessing the Systemic Health Risk of Perfluorooctanoate (PFOA)', Toxicological Sciences, vol. 163, no. 1, pp. 293-306. https://doi.org/10.1093/toxsci/kfy035
Convertino, Convertino ; Church, Timothy ; Olsen, Geary ; Liu, Yang ; Doyle, Eddie ; Elcombe, Clifford ; Barnett, Anna ; Samuel, Leslie ; MacPherson, Iain ; Evans, Thomas. / Stochastic Pharmacokinetic/Pharmacodynamic Modeling for Assessing the Systemic Health Risk of Perfluorooctanoate (PFOA). In: Toxicological Sciences. 2018 ; Vol. 163, No. 1. pp. 293-306.
@article{d281d8eb55ac48ce851a887b193e69bb,
title = "Stochastic Pharmacokinetic/Pharmacodynamic Modeling for Assessing the Systemic Health Risk of Perfluorooctanoate (PFOA)",
abstract = "A phase 1 dose-escalation trial assessed the chemotherapeutic potential of ammonium perfluorooctanoate (APFO). Forty-nine primarily solid-tumor cancer patients who failed standard therapy received weekly APFO doses (50–1200 mg) for 6 weeks. Clinical chemistries and plasma PFOA (anionic APFO) were measured predose and weekly thereafter. Several clinical measures including total cholesterol, high-density lipoproteins (HDLs), thyroid stimulating hormone (TSH), and free thyroxine (fT4), relative to PFOA concentrations were examined by: Standard statistical analyses using generalized estimating equations (GEE) and a probabilistic analysis using probability distribution functions (pdf) at various PFOA concentrations; and a 2-compartment pharmacokinetic/pharmacodynamic (PK/PD) model to directly estimate mean changes. Based on the GEE, the average rates of change in total cholesterol and fT4 associated with increasing PFOA were approximately ﰀ1.2ﰁ10ﰀ3 mmol/l/lM and2.8ﰁ10ﰀ3 pmol/l/lM, respectively. The PK/PD model predicted more closely the trends observed in the data as well as the pdfs of biomarkers. A decline in total cholesterol was observed, with a clear transition in shape and range of the pdfs, manifested by the maximum value of the Kullback-Leibler (KL) divergence, that occurred at plasma PFOA between 420 and 565 lM (175 000–230 000 ng/ml). High-density lipoprotein was unchanged. An increase in fT4 was observed at a higher PFOA transition point, albeit TSH was unchanged. Our findings are consistent with some animal models and may motivate re-examination of the epidemiologic studies to PFOA at levels several orders of magnitude lower than this study. These observational studies have reported contrary associations, but currently understood biology does not support the existence of such conflicting effects.",
keywords = "APFO, phase 1 trial, PK/PD modeling, cholesterol, PFOA, thyroid",
author = "Convertino Convertino and Timothy Church and Geary Olsen and Yang Liu and Eddie Doyle and Clifford Elcombe and Anna Barnett and Leslie Samuel and Iain MacPherson and Thomas Evans",
note = "This work was supported by the sponsor of this phase 1 clinical trial, CXR Biosciences (Dundee, UK). 3 M Company (St Paul, Minnesota) licensed a part of the database from CXR Biosciences for the purpose of the analyses presented herein.",
year = "2018",
month = "5",
day = "1",
doi = "10.1093/toxsci/kfy035",
language = "English",
volume = "163",
pages = "293--306",
journal = "Toxicological Sciences",
issn = "1096-6080",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Stochastic Pharmacokinetic/Pharmacodynamic Modeling for Assessing the Systemic Health Risk of Perfluorooctanoate (PFOA)

AU - Convertino, Convertino

AU - Church, Timothy

AU - Olsen, Geary

AU - Liu, Yang

AU - Doyle, Eddie

AU - Elcombe, Clifford

AU - Barnett, Anna

AU - Samuel, Leslie

AU - MacPherson, Iain

AU - Evans, Thomas

N1 - This work was supported by the sponsor of this phase 1 clinical trial, CXR Biosciences (Dundee, UK). 3 M Company (St Paul, Minnesota) licensed a part of the database from CXR Biosciences for the purpose of the analyses presented herein.

PY - 2018/5/1

Y1 - 2018/5/1

N2 - A phase 1 dose-escalation trial assessed the chemotherapeutic potential of ammonium perfluorooctanoate (APFO). Forty-nine primarily solid-tumor cancer patients who failed standard therapy received weekly APFO doses (50–1200 mg) for 6 weeks. Clinical chemistries and plasma PFOA (anionic APFO) were measured predose and weekly thereafter. Several clinical measures including total cholesterol, high-density lipoproteins (HDLs), thyroid stimulating hormone (TSH), and free thyroxine (fT4), relative to PFOA concentrations were examined by: Standard statistical analyses using generalized estimating equations (GEE) and a probabilistic analysis using probability distribution functions (pdf) at various PFOA concentrations; and a 2-compartment pharmacokinetic/pharmacodynamic (PK/PD) model to directly estimate mean changes. Based on the GEE, the average rates of change in total cholesterol and fT4 associated with increasing PFOA were approximately ﰀ1.2ﰁ10ﰀ3 mmol/l/lM and2.8ﰁ10ﰀ3 pmol/l/lM, respectively. The PK/PD model predicted more closely the trends observed in the data as well as the pdfs of biomarkers. A decline in total cholesterol was observed, with a clear transition in shape and range of the pdfs, manifested by the maximum value of the Kullback-Leibler (KL) divergence, that occurred at plasma PFOA between 420 and 565 lM (175 000–230 000 ng/ml). High-density lipoprotein was unchanged. An increase in fT4 was observed at a higher PFOA transition point, albeit TSH was unchanged. Our findings are consistent with some animal models and may motivate re-examination of the epidemiologic studies to PFOA at levels several orders of magnitude lower than this study. These observational studies have reported contrary associations, but currently understood biology does not support the existence of such conflicting effects.

AB - A phase 1 dose-escalation trial assessed the chemotherapeutic potential of ammonium perfluorooctanoate (APFO). Forty-nine primarily solid-tumor cancer patients who failed standard therapy received weekly APFO doses (50–1200 mg) for 6 weeks. Clinical chemistries and plasma PFOA (anionic APFO) were measured predose and weekly thereafter. Several clinical measures including total cholesterol, high-density lipoproteins (HDLs), thyroid stimulating hormone (TSH), and free thyroxine (fT4), relative to PFOA concentrations were examined by: Standard statistical analyses using generalized estimating equations (GEE) and a probabilistic analysis using probability distribution functions (pdf) at various PFOA concentrations; and a 2-compartment pharmacokinetic/pharmacodynamic (PK/PD) model to directly estimate mean changes. Based on the GEE, the average rates of change in total cholesterol and fT4 associated with increasing PFOA were approximately ﰀ1.2ﰁ10ﰀ3 mmol/l/lM and2.8ﰁ10ﰀ3 pmol/l/lM, respectively. The PK/PD model predicted more closely the trends observed in the data as well as the pdfs of biomarkers. A decline in total cholesterol was observed, with a clear transition in shape and range of the pdfs, manifested by the maximum value of the Kullback-Leibler (KL) divergence, that occurred at plasma PFOA between 420 and 565 lM (175 000–230 000 ng/ml). High-density lipoprotein was unchanged. An increase in fT4 was observed at a higher PFOA transition point, albeit TSH was unchanged. Our findings are consistent with some animal models and may motivate re-examination of the epidemiologic studies to PFOA at levels several orders of magnitude lower than this study. These observational studies have reported contrary associations, but currently understood biology does not support the existence of such conflicting effects.

KW - APFO

KW - phase 1 trial

KW - PK/PD modeling

KW - cholesterol

KW - PFOA

KW - thyroid

U2 - 10.1093/toxsci/kfy035

DO - 10.1093/toxsci/kfy035

M3 - Article

VL - 163

SP - 293

EP - 306

JO - Toxicological Sciences

JF - Toxicological Sciences

SN - 1096-6080

IS - 1

ER -